ZANTAC 300 Drug Patent Profile

✉ Email this page to a colleague

When do Zantac 300 patents expire, and when can generic versions of Zantac 300 launch?

Zantac 300 is a drug marketed by Glaxosmithkline and Glaxo Grp Ltd and is included in two NDAs.

The generic ingredient in ZANTAC 300 is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zantac 300

A generic version of ZANTAC 300 was approved as ranitidine hydrochloride by SANDOZ on August 29^th, 1997.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for ZANTAC 300?
What are the global sales for ZANTAC 300?
What is Average Wholesale Price for ZANTAC 300?

Summary for ZANTAC 300

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	35
Clinical Trials:	22
Patent Applications:	2,243
DailyMed Link:	ZANTAC 300 at DailyMed

Drug patent expirations by year for ZANTAC 300

Recent Clinical Trials for ZANTAC 300

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Spaulding Clinical Research LLC	Phase 1
Food and Drug Administration (FDA)	Phase 1
Dalhousie University	Phase 4

See all ZANTAC 300 clinical trials

US Patents and Regulatory Information for ZANTAC 300

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	ZANTAC 300	ranitidine hydrochloride	CAPSULE;ORAL	020095-002	Mar 8, 1994		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Glaxo Grp Ltd	ZANTAC 300	ranitidine hydrochloride	TABLET;ORAL	018703-002	Dec 9, 1985		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for ZANTAC 300

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	ZANTAC 300	ranitidine hydrochloride	CAPSULE;ORAL	020095-002	Mar 8, 1994	⤷ Sign Up	⤷ Sign Up
Glaxo Grp Ltd	ZANTAC 300	ranitidine hydrochloride	TABLET;ORAL	018703-002	Dec 9, 1985	⤷ Sign Up	⤷ Sign Up
Glaxo Grp Ltd	ZANTAC 300	ranitidine hydrochloride	TABLET;ORAL	018703-002	Dec 9, 1985	⤷ Sign Up	⤷ Sign Up
Glaxo Grp Ltd	ZANTAC 300	ranitidine hydrochloride	TABLET;ORAL	018703-002	Dec 9, 1985	⤷ Sign Up	⤷ Sign Up
Glaxosmithkline	ZANTAC 300	ranitidine hydrochloride	CAPSULE;ORAL	020095-002	Mar 8, 1994	⤷ Sign Up	⤷ Sign Up
Glaxosmithkline	ZANTAC 300	ranitidine hydrochloride	CAPSULE;ORAL	020095-002	Mar 8, 1994	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for ZANTAC 300

See the table below for patents covering ZANTAC 300 around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Slovakia	277922		⤷ Sign Up
Ireland	63179	Pharmaceutical capsules containing ranitidine	⤷ Sign Up
Japan	H0262822	MEMBRANE COATED TABLET	⤷ Sign Up
Netherlands	192819		⤷ Sign Up
Luxembourg	87681		⤷ Sign Up
Zimbabwe	1790	PHARMACEUTICAL COMPOSITIONS	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for ZANTAC 300

Recent Clinical Trials for ZANTAC 300

Make Better Decisions: Try a trial or see plans & pricing